Oncotelic Therapeutics Announces Phase 1 Trial Enrollment for Novel Intravenous Everolimus Formulation in Australia
Oncotelic Therapeutics has opened enrollment for the first clinical trial of Sapu-003, an intravenous Deciparticle formulation of everolimus that represents a significant advancement in mTOR-targeted cancer therapy delivery for patients with advanced breast cancer and other malignancies.
Oncotelic Therapeutics, through its joint venture GMP Biotechnology Ltd. with Dragon Overseas Capital Ltd., has initiated patient enrollment for a Phase 1 clinical trial of Sapu-003, marking the first clinical evaluation of an intravenous Deciparticle formulation of everolimus. The trial, designated ACTRN12625001083482, is currently enrolling patients with advanced HR+/HER2– breast cancer or other mTOR-sensitive tumors at leading oncology centers across Australia. This development represents a potential breakthrough in cancer treatment delivery systems that could improve therapeutic outcomes for patients with difficult-to-treat malignancies.
The significance of this trial extends beyond the specific drug candidate to the novel delivery technology itself. Sapu-003 utilizes the Deciparticle platform to create an intravenous formulation of everolimus, an established mTOR inhibitor used in breast cancer and other cancers. Traditional formulations of mTOR inhibitors have faced limitations in bioavailability and delivery efficiency, which this new approach aims to overcome. The ability to administer everolimus intravenously through this specialized particle system could potentially enhance drug distribution, improve targeting of cancer cells, and reduce side effects associated with current oral formulations.
Dr. Vuong Trieu, CEO of Sapu Nano and Oncotelic, emphasized the importance of this advancement, stating that Sapu-003 represents a significant advance in the delivery of mTOR-targeted therapies. The collaborative nature of this development, involving partnerships with SOCRU, Ingenū, and Medicilon, underscores the complexity and resource requirements of bringing innovative cancer treatments to clinical testing. These strategic alliances are designed to accelerate the development timeline and increase the likelihood of successfully bringing this next-generation treatment to patients with advanced cancers who have limited therapeutic options.
The trial's initiation follows recent presentation of research data at the 8th Australian Translational Breast Cancer Research Symposium, where Sapu Nano presented its poster detailing the preclinical development and rationale for Sapu-003. The selection of Australia for the Phase 1 trial reflects the country's robust clinical research infrastructure and regulatory environment that supports innovative cancer drug development. Patients participating in the study will be closely monitored for safety, tolerability, and preliminary efficacy signals that could support further clinical development.
For investors and stakeholders following Oncotelic's progress, additional information is available through the company's newsroom at https://ibn.fm/OTLC. The successful development of Sapu-003 could potentially address significant unmet needs in cancer treatment, particularly for patients with advanced HR+/HER2– breast cancer who have developed resistance to standard therapies. As enrollment progresses, the oncology community will be watching closely for results that could validate this novel approach to drug delivery and potentially expand treatment options for multiple cancer types sensitive to mTOR inhibition.